Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis

Yuechao Zhao, Ping Gong, Yiru Chen, Jerome C. Nwachukwu, Sathish Srinivasan, CheMyong Ko, Milan K Bagchi, Robert N. Taylor, Kenneth S. Korach, Kendall W. Nettles, John A. Katzenellenbogen, Benita S Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

Estrogenic and inflammatory components play key roles in a broad range of diseases including endometriosis, a common estrogen-dependent gynecological disorder in which endometrial tissue creates inflammatory lesions at extrauterine sites, causing pelvic pain and reduced fertility. Current medical therapies focus primarily on reducing systemic levels of estrogens, but these are of limited effectiveness and have considerable side effects. We developed estrogen receptor (ER) ligands, chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), which showed strong ER-dependent anti-inflammatory activity in a preclinical model of endometriosis that recapitulates the estrogen dependence and inflammatory responses of the disease in immunocompetent mice and in primary human endometriotic stromal cells in culture. Estrogen-dependent phenomena, including cell proliferation, cyst formation, vascularization, and lesion growth, were all arrested by CLI or OBHS, which prevented lesion expansion and also elicited regression of established lesions, suppressed inflammation, angiogenesis, and neurogenesis in the lesions, and interrupted crosstalk between lesion cells and infiltrating macrophages. Studies in ERα or ERβ knockout mice indicated that ERα is the major mediator of OBHS effectiveness and ERβ is dominant in CLI actions, implying involvement of both ERs in endometriosis. Neither ligand altered estrous cycling or fertility at doses that were effective for suppression of endometriosis. Hence, CLI and OBHS are able to restrain endometriosis by dual suppression of the estrogen-inflammatory axis. Our findings suggest that these compounds have the desired characteristics of preventive and therapeutic agents for clinical endometriosis and possibly other estrogen-driven and inflammation-promoted disorders.

Original languageEnglish (US)
Article number271ra9
JournalScience Translational Medicine
Volume7
Issue number271
DOIs
StatePublished - Jan 21 2015

Fingerprint

Endometriosis
Estrogen Receptors
Estrogens
Fertility
Ligands
Inflammation
Pelvic Pain
Neurogenesis
Stromal Cells
Knockout Mice
Cysts
Anti-Inflammatory Agents
Cell Culture Techniques
Macrophages
Cell Proliferation
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. / Zhao, Yuechao; Gong, Ping; Chen, Yiru; Nwachukwu, Jerome C.; Srinivasan, Sathish; Ko, CheMyong; Bagchi, Milan K; Taylor, Robert N.; Korach, Kenneth S.; Nettles, Kendall W.; Katzenellenbogen, John A.; Katzenellenbogen, Benita S.

In: Science Translational Medicine, Vol. 7, No. 271, 271ra9, 21.01.2015.

Research output: Contribution to journalArticle

Zhao, Y, Gong, P, Chen, Y, Nwachukwu, JC, Srinivasan, S, Ko, C, Bagchi, MK, Taylor, RN, Korach, KS, Nettles, KW, Katzenellenbogen, JA & Katzenellenbogen, BS 2015, 'Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis', Science Translational Medicine, vol. 7, no. 271, 271ra9. https://doi.org/10.1126/scitranslmed.3010626
Zhao, Yuechao ; Gong, Ping ; Chen, Yiru ; Nwachukwu, Jerome C. ; Srinivasan, Sathish ; Ko, CheMyong ; Bagchi, Milan K ; Taylor, Robert N. ; Korach, Kenneth S. ; Nettles, Kendall W. ; Katzenellenbogen, John A. ; Katzenellenbogen, Benita S. / Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. In: Science Translational Medicine. 2015 ; Vol. 7, No. 271.
@article{137b07d5fe694fc6a4c5f281286c2211,
title = "Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis",
abstract = "Estrogenic and inflammatory components play key roles in a broad range of diseases including endometriosis, a common estrogen-dependent gynecological disorder in which endometrial tissue creates inflammatory lesions at extrauterine sites, causing pelvic pain and reduced fertility. Current medical therapies focus primarily on reducing systemic levels of estrogens, but these are of limited effectiveness and have considerable side effects. We developed estrogen receptor (ER) ligands, chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), which showed strong ER-dependent anti-inflammatory activity in a preclinical model of endometriosis that recapitulates the estrogen dependence and inflammatory responses of the disease in immunocompetent mice and in primary human endometriotic stromal cells in culture. Estrogen-dependent phenomena, including cell proliferation, cyst formation, vascularization, and lesion growth, were all arrested by CLI or OBHS, which prevented lesion expansion and also elicited regression of established lesions, suppressed inflammation, angiogenesis, and neurogenesis in the lesions, and interrupted crosstalk between lesion cells and infiltrating macrophages. Studies in ERα or ERβ knockout mice indicated that ERα is the major mediator of OBHS effectiveness and ERβ is dominant in CLI actions, implying involvement of both ERs in endometriosis. Neither ligand altered estrous cycling or fertility at doses that were effective for suppression of endometriosis. Hence, CLI and OBHS are able to restrain endometriosis by dual suppression of the estrogen-inflammatory axis. Our findings suggest that these compounds have the desired characteristics of preventive and therapeutic agents for clinical endometriosis and possibly other estrogen-driven and inflammation-promoted disorders.",
author = "Yuechao Zhao and Ping Gong and Yiru Chen and Nwachukwu, {Jerome C.} and Sathish Srinivasan and CheMyong Ko and Bagchi, {Milan K} and Taylor, {Robert N.} and Korach, {Kenneth S.} and Nettles, {Kendall W.} and Katzenellenbogen, {John A.} and Katzenellenbogen, {Benita S}",
year = "2015",
month = "1",
day = "21",
doi = "10.1126/scitranslmed.3010626",
language = "English (US)",
volume = "7",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "271",

}

TY - JOUR

T1 - Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis

AU - Zhao, Yuechao

AU - Gong, Ping

AU - Chen, Yiru

AU - Nwachukwu, Jerome C.

AU - Srinivasan, Sathish

AU - Ko, CheMyong

AU - Bagchi, Milan K

AU - Taylor, Robert N.

AU - Korach, Kenneth S.

AU - Nettles, Kendall W.

AU - Katzenellenbogen, John A.

AU - Katzenellenbogen, Benita S

PY - 2015/1/21

Y1 - 2015/1/21

N2 - Estrogenic and inflammatory components play key roles in a broad range of diseases including endometriosis, a common estrogen-dependent gynecological disorder in which endometrial tissue creates inflammatory lesions at extrauterine sites, causing pelvic pain and reduced fertility. Current medical therapies focus primarily on reducing systemic levels of estrogens, but these are of limited effectiveness and have considerable side effects. We developed estrogen receptor (ER) ligands, chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), which showed strong ER-dependent anti-inflammatory activity in a preclinical model of endometriosis that recapitulates the estrogen dependence and inflammatory responses of the disease in immunocompetent mice and in primary human endometriotic stromal cells in culture. Estrogen-dependent phenomena, including cell proliferation, cyst formation, vascularization, and lesion growth, were all arrested by CLI or OBHS, which prevented lesion expansion and also elicited regression of established lesions, suppressed inflammation, angiogenesis, and neurogenesis in the lesions, and interrupted crosstalk between lesion cells and infiltrating macrophages. Studies in ERα or ERβ knockout mice indicated that ERα is the major mediator of OBHS effectiveness and ERβ is dominant in CLI actions, implying involvement of both ERs in endometriosis. Neither ligand altered estrous cycling or fertility at doses that were effective for suppression of endometriosis. Hence, CLI and OBHS are able to restrain endometriosis by dual suppression of the estrogen-inflammatory axis. Our findings suggest that these compounds have the desired characteristics of preventive and therapeutic agents for clinical endometriosis and possibly other estrogen-driven and inflammation-promoted disorders.

AB - Estrogenic and inflammatory components play key roles in a broad range of diseases including endometriosis, a common estrogen-dependent gynecological disorder in which endometrial tissue creates inflammatory lesions at extrauterine sites, causing pelvic pain and reduced fertility. Current medical therapies focus primarily on reducing systemic levels of estrogens, but these are of limited effectiveness and have considerable side effects. We developed estrogen receptor (ER) ligands, chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), which showed strong ER-dependent anti-inflammatory activity in a preclinical model of endometriosis that recapitulates the estrogen dependence and inflammatory responses of the disease in immunocompetent mice and in primary human endometriotic stromal cells in culture. Estrogen-dependent phenomena, including cell proliferation, cyst formation, vascularization, and lesion growth, were all arrested by CLI or OBHS, which prevented lesion expansion and also elicited regression of established lesions, suppressed inflammation, angiogenesis, and neurogenesis in the lesions, and interrupted crosstalk between lesion cells and infiltrating macrophages. Studies in ERα or ERβ knockout mice indicated that ERα is the major mediator of OBHS effectiveness and ERβ is dominant in CLI actions, implying involvement of both ERs in endometriosis. Neither ligand altered estrous cycling or fertility at doses that were effective for suppression of endometriosis. Hence, CLI and OBHS are able to restrain endometriosis by dual suppression of the estrogen-inflammatory axis. Our findings suggest that these compounds have the desired characteristics of preventive and therapeutic agents for clinical endometriosis and possibly other estrogen-driven and inflammation-promoted disorders.

UR - http://www.scopus.com/inward/record.url?scp=84921725208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921725208&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3010626

DO - 10.1126/scitranslmed.3010626

M3 - Article

C2 - 25609169

AN - SCOPUS:84921725208

VL - 7

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 271

M1 - 271ra9

ER -